Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Oran, BetülAhn, Kwang Woo
Fretham, Caitrin
Beitinjaneh, Amer
Bashey, Asad
Pawarode, Attaphol
Wirk, Baldeep
Scott, Bart L.
Savani, Bipin N.
Bredeson, Christopher
Weisdorf, Daniel
Marks, David I.
Rizzieri, David
Copelan, Edward
Hildebrandt, Gerhard C.
Hale, Gregory A.
Murthy, Hemant S.
Lazarus, Hillard M.
Cerny, Jan
Liesveld, Jane L.
Yared, Jean A.
Yves-Cahn, Jean
Szer, Jeffrey
Verdonck, Leo F.
Aljurf, Mahmoud
van der Poel, Marjolein
Litzow, Mark
Kalaycio, Matt
Grunwald, Michael R.
Diaz, Miguel Angel
Sabloff, Mitchell
Kharfan-Dabaja, Mohamed A.
Majhail, Navneet S.
Farhadfar, Nosha
Reshef, Ran
Olsson, Richard F.
Gale, Robert Peter
Nakamura, Ryotaro
Seo, Sachiko
Chhabra, Saurabh
Hashmi, Shahrukh
Farhan, Shatha
Ganguly, Siddhartha
Nathan, Sunita
Nishihori, Taiga
Jain, Tania
Agrawal, Vaibhav
Bacher, Ulrike
Popat, Uday
Saber, Wael
Date
2021-11Journal
Transplantation and Cellular TherapyPublisher
Elsevier BVType
Article
Metadata
Show full item recordRights/Terms
© 2021 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.Identifier to cite or link to this item
http://hdl.handle.net/10713/17544ae974a485f413a2113503eed53cd6c53
10.1016/j.jtct.2021.08.007